RecruitingNot applicableNCT07292987
Implementation and Evaluation of a Post-Diagnostic Announcement Protocol at the CRMR RefeRet, Quinze-Vingts Hospital
Studying Retinitis pigmentosa
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
- Principal Investigator
- Isabelle Audo, Pr, M.DCRMR Centre Hospitalier National D' Ophtalmologie Des Quinze-Vingts
- Intervention
- Enhanced post-diagnostic support(behavioral)
- Enrollment
- 80 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2025 – 2028
Study locations (1)
- Centre Hospitalier National D' Ophtalmologie Des Quinze-Vingts, Paris, Île-de-France Region, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07292987 on ClinicalTrials.govOther trials for Retinitis pigmentosa
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07502664Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)Ray Therapeutics, Inc.
- RECRUITINGNANCT07266584Restoration of Central Vision With PRIMA in Patients With Photoreceptor DegenerationScience Corporation
- RECRUITINGNCT07228793Natural History Study of Patients With EYS-Associated RPSensor Technology for Deafblind
- RECRUITINGPHASE1, PHASE2NCT06891885A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis PigmentosaSumitomo Pharma America, Inc.
- RECRUITINGPHASE2NCT07174726A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis PigmentosaBeacon Therapeutics
- RECRUITINGPHASE2NCT06628947A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis PigmentosaKiora Pharmaceuticals, Inc.
- RECRUITINGPHASE2NCT06912633Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)jCyte, Inc
- RECRUITINGNCT06982417InsightRP2 RegistryUniversity of Göttingen